NCT02826928View on ClinicalTrials.gov

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

NACompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

October 26, 2016

Primary Completion Date

February 28, 2020

Study Completion Date

June 3, 2022

Conditions

Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)

Interventions

BIOLOGICAL

blood sample withdrawn

Trial Locations (1)

51092

Chu Reims, Reims

All Listed Sponsors

lead

CHU de Reims

OTHER

NCT02826928 - Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter